Dronabinol

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Leadership, Central nervous system, Company, Agitation, Pittsburgh Sleep Quality Index, Private Securities Litigation Reform Act, Research, Tourette syndrome, GLOBE, Hypotension, Comprehension, Autism, FDA, Memory, Apathy, Judgement, Language, Insomnia, Appetite, Dementia, Nasdaq, Cannabinoid, Neurodegeneration, Intention, CMAI, Edinburgh, Psychosis, Attention, Mini–Mental State Examination, CBD, Delirium, Edinburgh Feeding Evaluation in Dementia Scale, Annual report, U.S. Securities and Exchange Commission, Government budget balance, Medicine, Status epilepticus, THC, Tolerability, Falls, Disease, SEC, Pain, Pharmaceutical industry, Medical device, Medical imaging, Patient, Dronabinol, Alzheimer's disease, Safety

Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.

Key Points: 
  • Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.
  • This Phase IIa clinical trial is an open label study, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.
  • The interim results summarize the data from the first eight patients who completed the study as per protocol.
  • We are pleased that SCI-110 is showing clinically meaningful results and may provide a potential treatment option for Alzheimers patients with agitation, said Adi Zuloff-Shani, PhD, Chief Technology Officer of SciSparc.

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Physician, Dronabinol, Cannabis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Lennox–Gastaut syndrome, CAGR, U.S. FDA, Alzheimer's disease, Seizure, Epilepsy, Vomiting, US, Dravet syndrome, COVID-19, Pharmaceutical industry, Medicinal plants, Drug, Cannabidiol, Nabilone, Fibromyalgia, Application

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Physician, Dronabinol, Cannabis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Lennox–Gastaut syndrome, CAGR, U.S. FDA, Alzheimer's disease, Seizure, Epilepsy, Vomiting, US, Dravet syndrome, COVID-19, Pharmaceutical industry, Medicinal plants, Drug, Cannabidiol, Nabilone, Fibromyalgia, Application

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

Global Medical Marijuana Market Trends/Analysis Report 2022: A $65.8 Billion Industry by 2030 - Rapid Adoption of Cannabis in Therapeutic Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Oncology, Alternative Medicine, AIDS, Cannabis, Health, Natural Resources, Pharmaceutical, Migraine, Parkinson's disease, Chronic pain, Medical cannabis, Diabetes, Conditional sentence, Cannabis, Research, Dronabinol, Industry, Disease, Cannabidiol, WHO, FDA, Adoption, Arthritis, Growth, Pain management, THC, Policy, USD, AIDS, Timeline of cannabis laws in the United States, Investment, Intellectual property, Lists of diseases, Awareness, Drug, Poultry, CBD, Cancer, Epilepsy, Nabilone

The major factors attributed to the industry growth are the rapid adoption of cannabis in therapeutic applications and a surge in the number of countries legalizing the usage of medical marijuana.

Key Points: 
  • The major factors attributed to the industry growth are the rapid adoption of cannabis in therapeutic applications and a surge in the number of countries legalizing the usage of medical marijuana.
  • As per numerous studies, cannabis has shown positive results in the treatment of chronic diseases.
  • Thus, with the growing penetration of chronic disease throughout the globe, the industry is expected to see a steep rise in demand.
  • For instance, as per the data released by the WHO, the chronic disease burden was expected to reach 57% by 2020.

DGAP-News: Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand

Retrieved on: 
Thursday, September 1, 2022
DGAP, Chronic pain, SE, EU, CEO, Pain, Research, Sleep, News, Anxiety, Flower, Prescription, Tourette syndrome, Depression, Synbiotics, Social Problems, Pharmacy, MS, Epilepsy, Gesellschaft mit beschränkter Haftung, Dronabinol, Eye, Marketing, Patient, Security (finance), Nightclub, Drug

Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58)

Key Points: 
  • Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58)
    In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair.
  • SynBiotic SE will present its new brand Hempamed Rx at its own booth.
  • In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH.
  • "With Hempamed Rx, we are not only focusing on a new strong brand for medical cannabis, we are also further expanding our sales team under the SynBiotic Sales umbrella."

Khiron, the Global Leader in Medical Cannabis Launches New Cannabis Products in Europe including Stellar Genetics from California

Retrieved on: 
Thursday, September 1, 2022
THC, EU, Legislation, Good, Pharmacy, Risk, THIS, Prescription, TSX, Multimedia, NOR, Medicine, Intention, Company, News, Failure, United Kingdom, THE, Narcotic, SEDAR, Dronabinol, Acquisition, Patient, Nature, Pharmaceutical industry, Fine chemical, Risk management, Khiron Oonchaiyaphum, Target

This new product is based on Khiron's current top selling and effective extract formulation in Latin America.

Key Points: 
  • This new product is based on Khiron's current top selling and effective extract formulation in Latin America.
  • These varieties are very popular in California among consumers and patients and are in very high demand in Europe.
  • With our new medical products, we offer patients what they want and need.
  • About Khiron Life Sciences Corp.
    Khiron is a leading global medical cannabis company with core operations in Latin America and Europe.

DGAP-News: Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements

Retrieved on: 
Saturday, July 30, 2022
Acquisition, Euromed, EUR, CEO, OTC, Financial Oversight and Management Board for Puerto Rico, Marketing, Dronabinol, Company, Herbal, Parallel, Security (finance), Dietary supplement, Fine chemical, Brehna

With over 40 years of experience in phytotherapy, Arkopharma specialises in herbal medical products and food supplements.

Key Points: 
  • With over 40 years of experience in phytotherapy, Arkopharma specialises in herbal medical products and food supplements.
  • Arkopharma distributes its products, both, through direct distribution sites and through partner networks in more than 30 countries.
  • "Arkopharma represents an ideal addition to our Dermapharm portfolio and would enrich us in particular with excellent expertise in the areas of herbal medical products and food supplements.
  • Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

Clever Leaves strengthens German presence through expanded Cantourage partnership

Retrieved on: 
Monday, July 11, 2022
Partnership, LinkedIn, CEO, Industry, Pharmacy, Dronabinol, Company, Cannabidiol, BOCA, Diversified Specialty Institute Holdings, Inc., GLOBE, THC, Patient, API, Leaf, NASDAQ, Drug, Pharmaceutical industry, EU

Clever Leaves will supply Cantourage with high-THC dried flower product from the Companys Wappa strain, cultivated in Clever Leaves facility in Portugal, where the company operates approximately 25,000 m2 of actively producing GACP-certified greenhouse.

Key Points: 
  • Clever Leaves will supply Cantourage with high-THC dried flower product from the Companys Wappa strain, cultivated in Clever Leaves facility in Portugal, where the company operates approximately 25,000 m2 of actively producing GACP-certified greenhouse.
  • Cantourage will utilize Clever Leaves product to produce IQANNA 10 which will have one of the highest THC levels available in German pharmacies.
  • Clever Leaves and Cantourages expanded partnership further increases the range of international, high-quality medical cannabis products available to the EU market under Clever Leaves brand IQANNA and further strengthen the Company as a multinational operator.
  • Andres Fajardo, CEO of Clever Leaves, emphasized, This partnership expansion provides us the opportunity to continue fulfilling Clever Leaves commitment to patients around the world seeking high-quality, safe and efficacious medicinal cannabis solutions.

Medical Cannabis Innovator Khiron Continues Global Expansion as Industry Leader Throughout Europe and Latin America

Retrieved on: 
Tuesday, June 28, 2022
Petro, Insurance, Acquisition, Board of directors, View, Patient, Legislation, EBITDA, CBD, Dronabinol, Prescription, Growth, Company, Full Spectrum, Multimedia, United Kingdom, Partnership, Certification, Hospital, Environment, Disability, Quality of life, Pharmacy, THC, Samsung Medical Center, Board, Physician, Health care provider, Rancho Los Amigos National Rehabilitation Center, Nature, Drug, Pharmaceutical industry, Medicine, Generic drug, Fine chemical, Cancer, Q4, Teletón, Khiron Oonchaiyaphum

TORONTO, June 28, 2022 /PRNewswire/ - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe.

Key Points: 
  • TORONTO, June 28, 2022 /PRNewswire/ - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe.
  • This network of medical treatment clinics allows Khiron to collect evidence and conduct studies on the usage of medical cannabis.
  • Khiron is the leader in medical cannabis in Latin America with its unique vertically integrated approach and leverage of insurance coverage on its clinics.
  • About Khiron Life Sciences Corp.
    Khiron is a leading global medical cannabis company with expanding operations in Latin America and Europe.

Cantourage UK brings Together Pharma's Uganda-grown medical cannabis to the United Kingdom

Retrieved on: 
Monday, June 27, 2022
Patient, Farm, Cannabidiol, Tel Aviv Stock Exchange, Dronabinol, COO, Pharma, TASE, Power station, GACP, Compliance, United Kingdom, Contract, Partnership, Gesellschaft mit beschränkter Haftung, Pharmacy, Genetics, Knowledge, Generic drug, Medicinal plants, Fine chemical, Drug

Together Pharma's medical products are a strong addition to the offering of Cantourage Clinic, which prescribes medical cannabis to patients throughout the UK

Key Points: 
  • Together Pharma's medical products are a strong addition to the offering of Cantourage Clinic, which prescribes medical cannabis to patients throughout the UK
    LONDON, June 27, 2022 /PRNewswire/ --Cantourage UK and Israeli medical cannabis producer Together Pharma (TASE: TGTR) have brought the first Ugandan medical cannabis to the United Kingdom.
  • Cantourage UK, a subsidiary of Berlin-based European medical cannabis leader Cantourage, has successfully imported the dried flower products from Germany.
  • Cantourage UK will offer Together Pharma's high-THC, non-irradiated medical cannabis flowers to patients immediately through Cantourage Clinic.
  • Cantourage UK imports medical cannabis products from Germany into the UK and Channel Islands, supplying a broad range of products to patients throughout the country.